Connection
Maryam Asgari to Neoplasms
This is a "connection" page, showing publications Maryam Asgari has written about Neoplasms.
|
|
Connection Strength |
|
 |
|
 |
|
0.194 |
|
|
|
-
Ashrafzadeh S, Asgari MM, Geller AC. The Need for Critical Examination of Disparities in Immunotherapy and Targeted Therapy Use Among Patients With Cancer. JAMA Oncol. 2021 08 01; 7(8):1115-1116.
Score: 0.074
-
Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017 Apr; 76(4):632-638.
Score: 0.054
-
Brasky TM, Potter JD, Kristal AR, Patterson RE, Peters U, Asgari MM, Thornquist MD, White E. Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 2012 Mar; 23(3):431-44.
Score: 0.038
-
Hay JL, Meischke HW, Bowen DJ, Mayer J, Shoveller J, Press N, Asgari M, Berwick M, Burke W. Anticipating dissemination of cancer genomics in public health: a theoretical approach to psychosocial and behavioral challenges. Ann Behav Med. 2007 Nov-Dec; 34(3):275-86.
Score: 0.028